Compositions for expanding regulatory T cells (Treg) populations, and treating and ameliorating autoimmune diseases and conditions
View Patent ↗In alternative embodiments, provided are compositions, including e.g., isolated, synthetic or recombinant peptides or polypeptides, for: expanding regulatory T cells (Treg) populations; or, for treating, ameliorating, preventing or reversing a vascular inflammation, and Kawasaki disease (KD) or a pediatric acute vasculitis of the coronary arteries, including vascular coronary abnormalities and the same or similar types of acute or chronic vascular inflammatory abnormalities, and methods for making and using them. In one embodiment, provided are immunotherapies for promoting expansion of natural, regulatory T cells to establish, or re-establish, vascular homeostasis; or, for treating, reversing, preventing or ameliorating: a disease or condition associated with an autoimmune disease or condition; an immune-mediated vascular disorder; a disease or condition that is currently treated with intravenous immunoglobulin (WIG) therapy; a vascular coronary abnormality; an acute or a chronic vasculitis; an autoimmune inflammatory vasculitis; a T cell mediated pediatric vasculitis; Kawasaki disease (KD) or a pediatric acute vasculitis of the coronary arteries; atherosclerosis; rheumatoid arthritis or Juvenile Idiopathic Arthritis; an autoimmune disease or condition; or, a neoplastic hematological disorder such as a lymphoma (e.g., a T cell lymphoma) or a leukemia.
1. A pharmaceutical composition or a formulation comprising a plurality of isolated, synthetic or recombinant peptides or polypeptides comprising:
(SEQ ID NO: 1)
TAALGCLVKDYFPEP,
(SEQ ID NO: 2)
CLVKDYFPEPVTVSW,
(SEQ ID NO: 3)
SVFLFPPKPKDTLMI,
(SEQ ID NO: 9)
TFPAVLQSSGLYSLS,
(SEQ ID NO: 14)
TYRVVSVLTVLHQDW,
(SEQ ID NO: 16)
QGNVFSCSVMHEALH,
(SEQ ID NO: 22)
YFPEPVTVSWNSGAL,
(SEQ ID NO: 23)
VTVSWNSGALTSGVH,
(SEQ ID NO: 10)
LQSSGLYSLSSVVTV,
(SEQ ID NO: 11)
LYSLSSVVTVPSSSL,
(SEQ ID NO: 17)
SCSVMHEALHNHYTQ,
and
(SEQ ID NO: 45)
SVLTVLHQDWLNGKE,
and a pharmaceutically acceptable excipient.
2. The pharmaceutical composition or formulation of claim 1 , comprising a plurality of isolated, synthetic or recombinant peptides consisting essentially of:
(SEQ ID NO: 1)
TAALGCLVKDYFPEP,
(SEQ ID NO: 2)
CLVKDYFPEPVTVSW,
(SEQ ID NO: 3)
SVFLFPPKPKDTLMI,
(SEQ ID NO: 9)
TFPAVLQSSGLYSLS,
(SEQ ID NO: 14)
TYRVVSVLTVLHQDW,
(SEQ ID NO: 16)
QGNVFSCSVMHEALH,
(SEQ ID NO: 22)
YFPEPVTVSWNSGAL,
(SEQ ID NO: 23)
VTVSWNSGALTSGVH,
(SEQ ID NO: 10)
LQSSGLYSLSSVVTV,
(SEQ ID NO: 11)
LYSLSSVVTVPSSSL,
(SEQ ID NO: 17)
SCSVMHEALHNHYTQ,
and
(SEQ ID NO: 45)
SVLTVLHQDWLNGKE,
and a pharmaceutically acceptable excipient.
3. The pharmaceutical composition or formulation of claim 2 , comprising a plurality of isolated, synthetic or recombinant peptides consisting of:
(SEQ ID NO: 1)
TAALGCLVKDYFPEP,
(SEQ ID NO: 2)
CLVKDYFPEPVTVSW,
(SEQ ID NO: 3)
SVFLFPPKPKDTLMI,
(SEQ ID NO: 9)
TFPAVLQSSGLYSLS,
(SEQ ID NO: 14)
TYRVVSVLTVLHQDW,
(SEQ ID NO: 16)
QGNVFSCSVMHEALH,
(SEQ ID NO: 22)
YFPEPVTVSWNSGAL,
(SEQ ID NO: 23)
VTVSWNSGALTSGVH,
(SEQ ID NO: 10)
LQSSGLYSLSSVVTV,
(SEQ ID NO: 11)
LYSLSSVVTVPSSSL,
(SEQ ID NO: 17)
SCSVMHEALHNHYTQ,
and
(SEQ ID NO: 45)
SVLTVLHQDWLNGKE,
and a pharmaceutically acceptable excipient.
4. The pharmaceutical composition or formulation of claim 1 , wherein the pharmaceutical composition or formulation is a parenteral formulation; or the pharmaceutical composition or formulation is an oral or topical formulation.
5. The pharmaceutical composition or formulation of claim 1 , formulated as a sterile solution for injection.
6. The pharmaceutical composition or formulation of claim 1 , formulated as a liquid, an emulsion, a lyophilized powder, a spray, a cream, a lotion, a controlled release formulation, a tablet, a pill, a gel, a patch, in an implant or in a spray.
7. The pharmaceutical composition or formulation of claim 1 , wherein the pharmaceutical composition or formulation is a subcutaneous, an intravenous (IV), an intradermal, an intramuscular, an intraperitoneal, an intranasal, a transdermal or a buccal route formulation.
8. The pharmaceutical composition or formulation of claim 1 , wherein the pharmaceutical composition or formulation is an inhaled powder.
9. The pharmaceutical composition or formulation of claim 1 , wherein the pharmaceutical composition or formulation is a controlled release formulation.
10. The pharmaceutical composition or formulation of claim 1 , wherein the pharmaceutical composition or formulation is a tablet, a pill, a gel, a patch, in an implant or a spray formulation.
11. The pharmaceutical composition or formulation of claim 1 , formulated as a sterile solution for injection.
12. The pharmaceutical composition or formulation of claim 1 , formulated as a powder.
13. The pharmaceutical composition or formulation of claim 1 , formulated as a lyophilized or freeze-dried composition.
14. The pharmaceutical composition or formulation of claim 1 , formulated as an aqueous or a non-aqueous isotonic sterile injection solution or formulated an aqueous or a non-aqueous sterile suspension.
15. The pharmaceutical composition or formulation of claim 1 , wherein the plurality of peptides or polypeptides are synthetic peptides or polypeptides.
16. The pharmaceutical composition or formulation of claim 1 , wherein the plurality of peptides or polypeptides are recombinant peptides or polypeptides.
17. A liposome comprising: a pharmaceutical or formulation of claim 1 .
18. A nanoparticle comprising: a pharmaceutical or formulation of claim 1 .
19. A vaccine comprising a pharmaceutical or formulation of claim 1 .
20. The vaccine of claim 19 , further comprises an adjuvant.
21. The vaccine of claim 20 , wherein the adjuvant comprises an incomplete adjuvant.